Back to discover

Protein / target

Glycogen synthase kinase-3 beta

Encoded byGSK3BP49841Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
2
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Protein kinase A catalytic subunit binding

Strongest disease association

Bipolar Disorder

Via encoding gene GSK3B · Clinical evidence · score 0.61

Therapeutic position

Established drug target

Small molecules

Research activity

Emerging research

5 papers · latest 2025

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1,…

View complete UniProt function annotation

Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1 (PubMed:11430833, PubMed:12554650, PubMed:14690523, PubMed:16484495, PubMed:1846781, PubMed:20937854, PubMed:9072970). Requires primed phosphorylation of the majority of its substrates (PubMed:11430833, PubMed:16484495). In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis (PubMed:8397507). May also mediate the development of insulin resistance by regulating activation of transcription factors (PubMed:8397507). Regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase (PubMed:8397507). In Wnt signaling, GSK3B forms a multimeric complex with APC, AXIN1 and CTNNB1/beta-catenin and phosphorylates the N-terminus of CTNNB1 leading to its degradation mediated by ubiquitin/proteasomes (PubMed:12554650). Phosphorylates JUN at sites proximal to its DNA-binding domain, thereby reducing its affinity for DNA (PubMed:1846781). Phosphorylates NFATC1/NFATC on conserved serine residues promoting NFATC1/NFATC nuclear export, shutting off NFATC1/NFATC gene regulation, and thereby opposing the action of calcineurin (PubMed:9072970). Phosphorylates MAPT/TAU on 'Thr-548', decreasing significantly MAPT/TAU ability to bind and stabilize microtubules (PubMed:14690523). MAPT/TAU is the principal component of neurofibrillary tangles in Alzheimer disease (PubMed:14690523). Plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex (PubMed:20937854). Phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair (By similarity). Probably regulates NF-kappa-B (NFKB1) at the transcriptional level and is required for the NF-kappa-B-mediated anti-apoptotic response to TNF (TNF/TNFA) (By similarity). Negatively regulates replication in pancreatic beta-cells, resulting in apoptosis, loss of beta-cells and diabetes (By similarity). Through phosphorylation of the anti-apoptotic protein MCL1, may control cell apoptosis in response to growth factors deprivation (By similarity). Phosphorylates MUC1 in breast cancer cells, decreasing the interaction of MUC1 with CTNNB1/beta-catenin (PubMed:9819408). Is necessary for the establishment of neuronal polarity and axon outgrowth (PubMed:20067585). Phosphorylates MARK2, leading to inhibition of its activity (By similarity). Phosphorylates SIK1 at 'Thr-182', leading to sustainment of its activity (PubMed:18348280). Phosphorylates ZC3HAV1 which enhances its antiviral activity (PubMed:22514281). Phosphorylates SNAI1, leading to its ubiquitination and proteasomal degradation (PubMed:15448698, PubMed:15647282, PubMed:25827072, PubMed:29059170). Phosphorylates SFPQ at 'Thr-687' upon T-cell activation (PubMed:20932480). Phosphorylates NR1D1 st 'Ser-55' and 'Ser-59' and stabilizes it by protecting it from proteasomal degradation. Regulates the circadian clock via phosphorylation of the major clock components including BMAL1, CLOCK and PER2 (PubMed:19946213, PubMed:28903391). Phosphorylates FBXL2 at 'Thr-404' and primes it for ubiquitination by the SCF(FBXO3) complex and proteasomal degradation (By similarity). Phosphorylates CLOCK AT 'Ser-427' and targets it for proteasomal degradation (PubMed:19946213). Phosphorylates BMAL1 at 'Ser-17' and 'Ser-21' and primes it for ubiquitination and proteasomal degradation (PubMed:28903391). Phosphorylates OGT at 'Ser-3' or 'Ser-4' which positively regulates its activity. Phosphorylates MYCN in neuroblastoma cells which may promote its degradation (PubMed:24391509). Regulates the circadian rhythmicity of hippocampal long-term potentiation and BMAL1 and PER2 expression (By similarity). Acts as a regulator of autophagy by mediating phosphorylation of KAT5/TIP60 under starvation conditions, activating KAT5/TIP60 acetyltransferase activity and promoting acetylation of key autophagy regulators, such as ULK1 and RUBCNL/Pacer (PubMed:30704899). Negatively regulates extrinsic apoptotic signaling pathway via death domain receptors. Promotes the formation of an anti-apoptotic complex, made of DDX3X, BRIC2 and GSK3B, at death receptors, including TNFRSF10B. The anti-apoptotic function is most effective with weak apoptotic signals and can be overcome by stronger stimulation (PubMed:18846110). Phosphorylates E2F1, promoting the interaction between E2F1 and USP11, stabilizing E2F1 and promoting its activity (PubMed:17050006, PubMed:28992046). Phosphorylates mTORC2 complex component RICTOR at 'Ser-1235' in response to endoplasmic stress, inhibiting mTORC2 (PubMed:21343617). Phosphorylates mTORC2 complex component RICTOR at 'Thr-1695' which facilitates FBXW7-mediated ubiquitination and subsequent degradation of RICTOR (PubMed:25897075). Acts as a negative regulator of smoothened signaling by mediating phosphorylation of GLI2 and GLI3 in absence of smoothened, promoting their processing by the SCF(BTRC) complex (PubMed:16705181). Phosphorylates FXR1, promoting FXR1 ubiquitination by the SCF(FBXO4) complex and FXR1 degradation by the proteasome (By similarity). Phosphorylates interleukin-22 receptor subunit IL22RA1, preventing its proteasomal degradation (By similarity). Phosphorylates and inhibits the CTP synthase and protein-asparagine deamidase activities of CTPS1 (PubMed:17681942). Phosphorylates DSP at multiple sequential serine residues in the C-terminus tail, promoting its recruitment to developing desmosome cell-cell junctions (PubMed:25733715)

Subcellular location

CytoplasmNucleusCell membrane
Domains and Gene Ontology detail (108)

Domains & features

Protein kinase

Gene Ontology

  • Caxon
  • Cbeta-catenin destruction complex
  • Ccentrosome
  • Ccytoplasm
  • Ccytosol
  • Cdendrite
  • Cendoplasmic reticulum lumen
  • Cglutamatergic synapse
  • Cmitochondrion
  • Cnucleoplasm
  • Cnucleus
  • Cplasma membrane

420 aa · 47 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationUniProt · GOExcitatory neurotransmissionGOReceptor tyrosine kinase signallingUniProtTranscriptional regulationUniProt · GOImmune signallingUniProt · GOMetabolic enzyme activityUniProt · GO
View supporting evidence

Cell migration

  • ·Constitutively active protein kinase that acts as a negative regulator in the hormonal c…
  • ·negative regulation of cell migration

Excitatory neurotransmission

  • ·glutamatergic synapse
  • ·excitatory postsynaptic potential

Receptor tyrosine kinase signalling

  • ·Constitutively active protein kinase that acts as a negative regulator in the hormonal c…

Transcriptional regulation

  • ·Constitutively active protein kinase that acts as a negative regulator in the hormonal c…
  • ·RNA polymerase II-specific DNA-binding transcription factor binding
  • ·negative regulation of gene expression
  • ·positive regulation of gene expression

Immune signalling

  • ·Constitutively active protein kinase that acts as a negative regulator in the hormonal c…
  • ·cellular response to interleukin-3

Metabolic enzyme activity

  • ·Constitutively active protein kinase that acts as a negative regulator in the hormonal c…
  • ·glycogen metabolic process

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

1 medicine · 2 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Bipolar Disorder1 medicine
Depressive Disorder1 medicine

2 medicines meet Open Targets' target-level approved-medicine definition; the 1 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

lithium carbonate
ApprovedInhibitor

Glycogen synthase kinase-3 inhibitor

Indicated for Bipolar Disorder, Depressive Disorder

Acts on a complex — shared with GSK3A · 1 of 3 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene GSK3B

Gene-level evidence surfaced through the gene GSK3Bthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Bipolar Disorder
0.76Well supported

Clinical evidence dominant · Open Targets 0.61

bipolar I disorder
0.70Moderately supported

Clinical evidence dominant · Open Targets 0.57

Major depressive disorder
0.70Moderately supported

Clinical evidence dominant · Open Targets 0.56

Alzheimer's Disease
0.51Moderately supported

Pathway evidence dominant · Open Targets 0.55

Neoplasms
0.46Limited support

Pathway evidence dominant · Open Targets 0.56

View evidence synthesis (5)
Bipolar DisorderWell supported
0.76
agreement 0.600.91
Clinical93%Literature7%

Open Targets aggregate 0.61 · 2 independent evidence families

bipolar I disorderModerately supported
0.70
agreement 0.550.86
Clinical99%Literature1%

Open Targets aggregate 0.57 · 2 independent evidence families

Major depressive disorderModerately supported
0.70
agreement 0.550.86
Clinical83%Literature17%

Open Targets aggregate 0.56 · 2 independent evidence families

Alzheimer's DiseaseModerately supported
0.51
agreement 0.400.63
Pathway55%Literature23%Clinical22%RNA expression1%

Open Targets aggregate 0.55 · 4 independent evidence families

NeoplasmsLimited support
0.46
agreement 0.330.59
Pathway66%Literature25%Clinical9%

Open Targets aggregate 0.56 · 3 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Bipolar Disorder0.61
bipolar I disorder0.57
Major depressive disorder0.56
Neoplasms0.56
Alzheimer's Disease0.55
Parkinson's Disease0.54
Multiple Sclerosis0.53
Neurodegenerative Diseases0.53
Lysosomal Storage Diseases0.51

Drug development

6 compounds recorded · 2 approved · 4 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (6)
AZD-1080Phase 1
TIDEGLUSIBPhase 2 3
LY-2090314Phase 2
LITHIUM CITRATEApproval
LITHIUM CARBONATEApproval
ELRAGLUSIBPhase 2

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (literature and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (11)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · High-Quality PocketSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confPR · LiteraturePR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

insulin resistanceBrennan et al. (2024)heart diseaseForce et al. (2011)female infertilityBrennan et al. (2024)male infertilityBrennan et al. (2024)regulation of catalytic activityToxCastCarcinogenicityBrennan et al. (2024)cardiac dysfunctionBrennan et al. (2024)renal failureBrennan et al. (2024)abnormal bone developmentBrennan et al. (2024)Mitochondrial toxicityBrennan et al. (2024)tissue hyperplasiaBrennan et al. (2024)neurotoxicityBrennan et al. (2024)

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

UNKNOWN · via lithium carbonate · NCT03056248

COMPLETED · via lithium carbonate · NCT00602537

COMPLETED · via lithium carbonate · NCT00641927

COMPLETED · via lithium carbonate · NCT00177567

ClinicalTrials.gov via the drug-target graph.

What's happening now

10

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Trial status changed2026-07-29

    A Randomized, Balanced, Phase 1, Multiple-dose, Open-label, Two-treatment, Two-period, Two-sequence, Crossover, Relative Bioavailability Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects

    Status changed to Completed · ClinicalTrials.gov · via lithium carbonate

  2. Label change2026-07-13

    Label change: LITHIUM CARBONATE (ANDA076832)

    fda · regulatory · fda · via lithium carbonate

  3. Label change2020-02-14

    Label change: LITHIUM CARBONATE (ANDA076832)

    fda · regulatory · fda · via lithium carbonate

  4. Label change2020-02-14

    Label change: LITHIUM CARBONATE (ANDA076832)

    fda · regulatory · fda · via lithium carbonate

  5. Label change2020-02-14

    Label change: LITHIUM CARBONATE (ANDA076832)

    fda · regulatory · fda · via lithium carbonate

  6. Label change2012-03-06

    Label change: LITHIUM CARBONATE (ANDA076832)

    fda · regulatory · fda · via lithium carbonate

  7. New publication2011-11-22
    Efficacy and safety of lithium carbonate treatment of chronic spinal cord injuries: a double-blind, randomized, placebo-controlled clinical trial.

    Spinal cord · 2012 · 41 citations · Europe PMC · via lithium carbonate

  8. Label change2007-12-26

    Label change: LITHIUM CARBONATE (ANDA076832)

    fda · regulatory · fda · via lithium carbonate

  9. Label change2007-09-28

    Label change: LITHIUM CARBONATE (ANDA076832)

    fda · regulatory · fda · via lithium carbonate

  10. Regulatory approval2004-10-28

    Approval: LITHIUM CARBONATE (ANDA076832)

    fda · regulatory · fda · via lithium carbonate

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.

Research activity

5 papers · to 2025

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.